Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study

BACKGROUND: Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 μg has been shown to improve lung function and health status, and reduce exacerbations, versus budesonide/formoterol in patients with chronic obstructive pulmonary disease (COPD). We evaluated the non-inf...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Respir Res
Glavni autori: Bremner, Peter R., Birk, Ruby, Brealey, Noushin, Ismaila, Afisi S., Zhu, Chang-Qing, Lipson, David A.
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2018
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5785849/
https://ncbi.nlm.nih.gov/pubmed/29370819
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-018-0724-0
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items